Paul Allen set aside funds to fight his disease

Matthias Stephan

Matthias Stephan, who studies lymphoma at Seattle’s Fred Hutchinson Cancer Research Center, is among 10 newly named Allen Distinguished Investigators. (Fred Hutch News Service Photo / Robert Hood)

It’s notable that the newest class of Allen Distinguished Investigators, announced today by the Paul G. Allen Frontiers Group, includes researchers who are developing new treatments for lymphoma. Lymphoma is the type of blood cancer that led to the death of Microsoft co-founder Paul Allen, the namesake and funder of the research program.

The decision to focus on that disease — along with nuclear biophysics, neuroimmunology, brain cells and Alzheimer’s disease, and cellular development and aging — was made last year, long before the billionaire philanthropist was diagnosed with a recurrence of his non-Hodgkin’s lymphoma. Nevertheless, the choice is in line with Allen’s willingness to tackle the toughest challenges in bioscience.

Get the full story on GeekWire.

About Alan Boyle

Aerospace and science editor for GeekWire, creator of Cosmic Log, author of "The Case for Pluto: How a Little Planet Made a Big Difference," president of the Council for the Advancement of Science Writing. Check out "About Alan Boyle" for more fun facts.
This entry was posted in GeekWire and tagged , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.